Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Relmada Therapeutics, Inc. (RLMD) had Weighted-Average Shares Outstanding (Diluted) of 112.44M for the most recently reported fiscal quarter, ending 2026-09-30.
| Income Statement Financials | |
-- |
|
$-13.86M |
|
-- |
|
-- |
|
$13.10M |
|
$-13.10M |
|
$-0.77M |
|
$-13.86M |
|
$-10.82M |
|
$-13.86M |
|
$-13.86M |
|
$-13.86M |
|
$-10.82M |
|
$-13.10M |
|
$-13.10M |
|
112.44M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
112.44M |
$-0.12 |
|
$-0.12 |
|
| Balance Sheet Financials | |
$205.05M |
|
-- |
|
$0.25M |
|
$205.30M |
|
$7.78M |
|
-- |
|
$3.78M |
|
$11.56M |
|
$193.74M |
|
$193.74M |
|
$193.74M |
|
106.69M |
|
| Cash Flow Statement Financials | |
$-37.26M |
|
$-110.69M |
|
$150.17M |
|
$3.50M |
|
$5.72M |
|
$2.22M |
|
$6.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
26.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-236.41M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-7.16% |
|
-7.16% |
|
-6.75% |
|
-7.16% |
|
$1.82 |
|
$-2.10 |
|
$-0.33 |
|